Recent Advances in the Treatment of Advanced HER2+ Breast Cancer: SABCS 2024 - Episode 3

T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights

January 29, 2025

Neil M. Iyengar, MD, Sara A. Hurvitz, MD, FACP , Laura Huppert, MD, Anne P. O’Dea, MD, Melinda L. Telli, MD

Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Precision Medicine in Breast Cancer: Evolving Paradigms in HER2 Testing and Clinical Implications

EP. 2: ADCs in HER2-Low Breast Cancer: Insights From DESTINY-Breast04, TROPiCS-02, and TROPION-Breast02

Now Viewing

EP. 3: T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights

EP. 4: Emerging Data and Treatment Considerations in HER2 Ultralow Breast Cancer

EP. 5: Patient-Reported Outcomes and Quality of Life Data With T-DXd in HER2-(Ultra) Low mBC

EP. 6: Proactive AE Management and Prophylactic Strategies With TADCs in Breast Cancer

EP. 7: Evolving Paradigms in HER2+ Advanced Breast Cancer With Brain Metastases

EP. 8: Precision in CNS Targeting: Optimizing Management of Brain Metastases in HER2+ Breast Cancer

EP. 9: Insights From DESTINY-Breast12 Evaluating T-DXd in HER2+ Breast Cancer and Active and Stable Brain Metastases

EP. 10: Novel and Emerging Strategies for HER2+ Breast Cancer With Brain Metastases

EP. 11: Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer

EP. 12: SABCS Highlights and Future Directions in the Treatment of Breast Cancer

Video content above is prompted by the following:

Please discuss the recent findings from the DESTINY-Breast06 trial, highlighting key efficacy and safety findings and their implications for the treatment of HER2-low/ultralow metastatic breast cancer.